KFF November 26, 2024
Juliette Cubanski, Elizabeth Williams

The Biden administration has proposed to allow Medicare and require Medicaid to cover drugs used to treat obesity by reinterpreting the statutory language that currently prohibits coverage of drugs used for weight loss under Medicare and permits but does not require states to cover these drugs for weight loss under Medicaid. This reinterpretation reflects an evolution in the understanding of obesity as a disease and weight loss as conferring real health benefits in people with obesity rather than being merely for cosmetic purposes. It also comes amidst high and growing demand for and use of a relatively new class of highly effective, but also very expensive, drugs being used to treat obesity, known as GLP-1s.

Under current law, people on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare, Patient / Consumer, Pharma / Biotech, Provider
High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Boosting biopharma R&D performance with a next-generation technology stack
Charting the path to patients
External innovation: Biopharma dealmaking to boost R&D productivity

Share This Article